Troy Cox

Troy Cox is a pioneer in the precision medicine revolution. Former CEO of Foundation Medicine (FMI) - acquired by Roche in 2018 - Troy is today making a difference in patient’s lives by serving on corporate boards of innovative companies in the Biopharma, Diagnostic, and Tech industries. He is also committing his support to patient-focused non-profit organizations.

In June 2019, Troy joined SOPHiA GENETICS’ Board of Directors to help the organization further advance Data-Driven Medicine.

Prior to Foundation Medicine, Troy served as Senior Vice President and Officer at Genentech where he led US BioOncology for a period of unprecedented growth, participating in the launch of nearly half of the products from the world’s oncology leader. Other notable experiences include UCB, Sanofi-Aventis and Schering-Plough.

Troy’s expertise spans across strategy, general management, commercial, and R&D. His pharmaceutical career began as a Sales Representative after earning his MBA at the University of Missouri. He also received a BBA in Finance from the University of Kentucky.